丹参联合醋酸曲安奈德注射液治疗口腔黏膜下纤维化的Meta分析
|
摘要
目的对丹参联合醋酸曲安奈德注射液治疗口腔黏膜下纤维化进行Meta分析。方法检索Pubmed、Web of Knowledge、CNKI、VIP等数据库(检索时限从建库至2018年1月)中丹参联合醋酸曲安奈德注射液与单用醋酸曲安奈德注射液治疗口腔黏膜下纤维化的随机对照试验,再通过Rev Man 5. 3软件进行Meta分析。结果共纳入5篇文献,236例患者,其中男性189例,女性47例。与对照组(单用醋酸曲安奈德注射液)比较,治疗后试验组(丹参联合醋酸曲安奈德注射液)张口度显著提高(P <0. 000 01),黏膜病损面积、VAS疼痛评分显著降低(P≤0. 05),同时2组不良反应发生率无显著性差异(P> 0. 05)。结论与单用醋酸曲安奈德注射液比较,联合丹参后可有效改善口腔黏膜下纤维化患者张口受限、疼痛症状,明显减小黏膜病损面积,而且不良反应发生率相当。
引文
[1] Wollina U,Verma S B,Ali F M,et al. Oral submucous fibrosis:an update[J]. Clin Cosmet Investig Dermatol,2015,8:193-204.
[2] Arakeri G,Rai K K,Hunasqi S,et al. Oral submucous fibrosis:An update on current theories of pathogenesis[J]. J Oral Pathol Med,2017,46(6):406-412.
[3] Pindborg J J,Sirsat S M. Oral submucous fibrosis[J]. Oral Surg Oral Med Oral Pathol,1966,22(6):764-779.
[4] Pindborg J J. Oral submucous fibrosis as a precancerous condition[J]. Scand J Dent Res,1984,92(3):224-229.
[5] Shanbhag V K L. Medical management of oral submucous fibrosis[J]. Asia Pac J Oncol Nurs,2015,2(1):51.
[6] Caro D V,Sutera F M,Giannola L I. In situ delivery of corticosteroids for treatment of oral diseases[J]. Ther Deliv,2017,8(10):899-914.
[7] Ameer N T,Shukla R K. A cross sectional study of oral submucous fibrosis in central India and the effect of local triamcinolone therapy[J]. Indian J Otolaryngol Head Neck Surg,2012,64(3):240-243.
[8] Gupta S,Ghosh S,Gupta S. Interventions for the management of oral lichen planus:a review of the conventional and novel therapies[J]. Oral Dis,2017,23(8):1029-1042.
[9] Singh M,Niranjan H S,Mehrotra R,et al. Efficacy of hydrocortisone acetate/hyaluronidase vs triamcinolone acetonide/hyaluronidase in the treatment of oral submucous fibrosis[J]. Indian J Med Res,2010,131:665-669.
[10] Siponen M,Huuskonen L,Kallio-Pulkkinen S,et al. Topical tacrolimus,triamcinolone acetonide,and placebo in oral lichen planus:a pilot randomized controlled trial[J]. Oral Dis,2017,23(5):660-668.
[11] Jonas J B,Kreissig I,Degenring R F. Treatment of oedematous,proliferative and neovascular diseases by intravitreal triamcinolone acetonide[J]. Klin Monbl Augenheilkd,2003,220(6):384-390.
[12] Yan X F,Zhao P,Ma D Y,et al. Salvianolic acid B protects hepatocytes from H2O2injury by stabilizing the lysosomal membrane[J]. World J Gastroenterol,2017,23(29):5333-5344.
[13] Yuan X L,Xiang Y J,Zhu N,et al. Salvianolic acid A protects against myocardial ischemia/reperfusion injury by reducing platelet activation and inflammation[J]. Exp Ther Med,2017,14(2):961-966.
[14]蔺瑞,段佳林,牟菲,等.丹参主要活性成分体内代谢途径及产物研究进展[J].中国新药杂志,2017,26(19):2271-2277.
[15] Jiang X W,Zhang Y,Yang S K,et al. Efficacy of salvianolic acid B combined with triamcinolone acetonide in the treatment of oral submucous fibrosis[J]. Oral Surg Oral Med Oral Pathol Oral Radiol,2013,115(3):339-344.
[16]左雯鑫,李晓宇,蔡淦英,等.复方丹参滴丸联合曲安奈德治疗口腔黏膜下纤维性变的临床研究[J].实用口腔医学杂志,2014,30(6):846-848.
[17]薛洪权,衣红梅.联用丹参注射液和曲安奈德注射液治疗口腔黏膜下纤维性变的效果观察[J].齐齐哈尔医学院学报,2016,37(29):3681-3682.
[18]贾金林.曲安奈德联合丹参注射液治疗不同程度口腔黏膜下纤维变性的疗效分析[J].贵州医药,2016,40(1):53-55.
[19]赵雁焕,徐梅,陆洋.丹参注射液联合曲安奈德局部注射治疗OSF的疗效及对血清TGF-β1、IL-6的影响[J].海南医学院学报,2017,23(5):673-675,679.
[20]邱喜丽.口腔黏膜下纤维化的疗效评估及wnt1的表达[D].长沙:中南大学,2013.
[21] Dahl J,Hammert W C. Overview of injectable corticosteroids[J]. J Hand Surg Am,2012,37(8):1715-1717.
[2] Arakeri G,Rai K K,Hunasqi S,et al. Oral submucous fibrosis:An update on current theories of pathogenesis[J]. J Oral Pathol Med,2017,46(6):406-412.
[3] Pindborg J J,Sirsat S M. Oral submucous fibrosis[J]. Oral Surg Oral Med Oral Pathol,1966,22(6):764-779.
[4] Pindborg J J. Oral submucous fibrosis as a precancerous condition[J]. Scand J Dent Res,1984,92(3):224-229.
[5] Shanbhag V K L. Medical management of oral submucous fibrosis[J]. Asia Pac J Oncol Nurs,2015,2(1):51.
[6] Caro D V,Sutera F M,Giannola L I. In situ delivery of corticosteroids for treatment of oral diseases[J]. Ther Deliv,2017,8(10):899-914.
[7] Ameer N T,Shukla R K. A cross sectional study of oral submucous fibrosis in central India and the effect of local triamcinolone therapy[J]. Indian J Otolaryngol Head Neck Surg,2012,64(3):240-243.
[8] Gupta S,Ghosh S,Gupta S. Interventions for the management of oral lichen planus:a review of the conventional and novel therapies[J]. Oral Dis,2017,23(8):1029-1042.
[9] Singh M,Niranjan H S,Mehrotra R,et al. Efficacy of hydrocortisone acetate/hyaluronidase vs triamcinolone acetonide/hyaluronidase in the treatment of oral submucous fibrosis[J]. Indian J Med Res,2010,131:665-669.
[10] Siponen M,Huuskonen L,Kallio-Pulkkinen S,et al. Topical tacrolimus,triamcinolone acetonide,and placebo in oral lichen planus:a pilot randomized controlled trial[J]. Oral Dis,2017,23(5):660-668.
[11] Jonas J B,Kreissig I,Degenring R F. Treatment of oedematous,proliferative and neovascular diseases by intravitreal triamcinolone acetonide[J]. Klin Monbl Augenheilkd,2003,220(6):384-390.
[12] Yan X F,Zhao P,Ma D Y,et al. Salvianolic acid B protects hepatocytes from H2O2injury by stabilizing the lysosomal membrane[J]. World J Gastroenterol,2017,23(29):5333-5344.
[13] Yuan X L,Xiang Y J,Zhu N,et al. Salvianolic acid A protects against myocardial ischemia/reperfusion injury by reducing platelet activation and inflammation[J]. Exp Ther Med,2017,14(2):961-966.
[14]蔺瑞,段佳林,牟菲,等.丹参主要活性成分体内代谢途径及产物研究进展[J].中国新药杂志,2017,26(19):2271-2277.
[15] Jiang X W,Zhang Y,Yang S K,et al. Efficacy of salvianolic acid B combined with triamcinolone acetonide in the treatment of oral submucous fibrosis[J]. Oral Surg Oral Med Oral Pathol Oral Radiol,2013,115(3):339-344.
[16]左雯鑫,李晓宇,蔡淦英,等.复方丹参滴丸联合曲安奈德治疗口腔黏膜下纤维性变的临床研究[J].实用口腔医学杂志,2014,30(6):846-848.
[17]薛洪权,衣红梅.联用丹参注射液和曲安奈德注射液治疗口腔黏膜下纤维性变的效果观察[J].齐齐哈尔医学院学报,2016,37(29):3681-3682.
[18]贾金林.曲安奈德联合丹参注射液治疗不同程度口腔黏膜下纤维变性的疗效分析[J].贵州医药,2016,40(1):53-55.
[19]赵雁焕,徐梅,陆洋.丹参注射液联合曲安奈德局部注射治疗OSF的疗效及对血清TGF-β1、IL-6的影响[J].海南医学院学报,2017,23(5):673-675,679.
[20]邱喜丽.口腔黏膜下纤维化的疗效评估及wnt1的表达[D].长沙:中南大学,2013.
[21] Dahl J,Hammert W C. Overview of injectable corticosteroids[J]. J Hand Surg Am,2012,37(8):1715-1717.